Shares in the Belgian biotech Galapagos have surged after a late stage trial of filgotinib, a rheumatoid arthritis drug it is developing with Gilead, met all its endpoints.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,